title: Tedizolid for treatment of acute bacterial skin and skin structure infections.
abstract: Tedizolid is a newly approved drug of the oxazolidinone class. It has high in vitro activity against Gram-positive bacteria, including multidrug-resistant strains. Peak plasma concentration of tedizolid is obtained within 3 h of oral dosing (PO), with high bioavailability. Tedizolid is mostly metabolized via the liver, and is excreted in feces in the form of a sulfate conjugate. Tedizolid 200 mg taken once daily demonstrated non-inferior efficacy and a good safety profile in patients with acute bacterial skin and skin structure infections. Results of two pivotal Phase III clinical trials showed that 6 days of 200 mg tedizolid PO or sequential intravenous (IV)/PO once-daily treatment was non-inferior to 10 days of 600 mg linezolid PO or sequential IV/PO twice-daily treatment at 48-72 h (primary end point) and at the test-of-cure in patients with acute bacterial skin and skin structure infections. The Phase II and Phase III trials also demonstrated that tedizolid was well tolerated.
authors.affiliation: Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Hui
authors.forename: Lü
authors.initials: L
authors.lastname: Xiaoju
mesh_terms: D000208:Acute Disease; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010755:Organophosphates / Q000494:pharmacology / Q000627:therapeutic use*; D010080:Oxazoles / Q000494:pharmacology / Q000627:therapeutic use*; D017192:Skin Diseases, Bacterial / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; C515040:tedizolid phosphate
keywords: acute bacterial superficial skin structure infections; efficacy; pharmacodynamics; pharmacokinetics; safety; tedizolid